Literature DB >> 9451021

The role of site-specific N-glycosylation in secretion of soluble forms of rabies virus glycoprotein.

B S Wojczyk1, M Stwora-Wojczyk, S Shakin-Eshleman, W H Wunner, S L Spitalnik.   

Abstract

Rabies virus glycoprotein is important in the biology and pathogenesis of neurotropic rabies virus infection. This transmembrane glycoprotein is the only viral protein on the surface of virus particles, is the viral attachment protein that facilitates virus uptake by the infected cell, and is the target of the host humoral immune response to infection. The extracellular domain of this glycoprotein has N-glycosylation sequons at Asn37, Asn247, and Asn319. Appropriate glycosylation of these sequons is important in the expression of the glycoprotein. Soluble forms of rabies virus glycoprotein were constructed by insertion of a stop codon just external to the transmembrane domain. Using site-directed mutagenesis and expression in transfected eukaryotic cells, it was possible to compare the effects of site-specific glycosylation on the cell-surface expression and secretion of transmembrane and soluble forms, respectively, of the same glycoprotein. These studies yielded the surprising finding that although any of the three sequons permitted cell surface expression of full-length rabies virus glycoprotein, only the N-glycan at Asn319 permitted secretion of soluble rabies virus glycoprotein. Despite its biological and medical importance, it has not yet been possible to determine the crystal structure of the full-length transmembrane form of rabies virus glycoprotein which contains heterogeneous oligosaccharides. The current studies demonstrate that a soluble form of rabies virus glycoprotein containing only one sequon at Asn319 is efficiently secreted in the presence of the N-glycan processing inhibitor 1-deoxymannojirimycin. Thus, it is possible to purify a conformationally relevant form of rabies virus glycoprotein that contains only one N-glycan with a substantial reduction in its microheterogeneity. This form of the glycoprotein may be particularly useful for future studies aimed at elucidating the three-dimensional structure of this important glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9451021     DOI: 10.1093/glycob/8.2.121

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  6 in total

1.  GlycoSuiteDB: a curated relational database of glycoprotein glycan structures and their biological sources. 2003 update.

Authors:  Catherine A Cooper; Hiren J Joshi; Mathew J Harrison; Marc R Wilkins; Nicolle H Packer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

2.  Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function.

Authors:  Bin Wang; Yujie Wang; Dylan A Frabutt; Xihe Zhang; Xiaoyu Yao; Dan Hu; Zhuo Zhang; Chaonan Liu; Shimin Zheng; Shi-Hua Xiang; Yong-Hui Zheng
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

3.  Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion.

Authors:  M Flamand; F Megret; M Mathieu; J Lepault; F A Rey; V Deubel
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 4.  The cell biology of rabies virus: using stealth to reach the brain.

Authors:  Matthias J Schnell; James P McGettigan; Christoph Wirblich; Amy Papaneri
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

5.  Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups.

Authors:  Christine R Fisher; David E Lowe; Todd G Smith; Yong Yang; Christina L Hutson; Christoph Wirblich; Gino Cingolani; Matthias J Schnell
Journal:  Cell Rep       Date:  2020-07-21       Impact factor: 9.423

Review 6.  Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.

Authors:  Braira Wahid; Amjad Ali; Muhammad Idrees; Shazia Rafique
Journal:  Cell Immunol       Date:  2016-08-03       Impact factor: 4.868

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.